Clinical trial
Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or…
NCT00380653 · Cyclacel Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00380653 |
|---|---|
| Title | Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes |
| Official title | A Phase I Pharmacologic Study of Oral Sapacitabine in Patients With Advanced Leukemias or Myelodysplastic Syndromes |
| Lead sponsor | Cyclacel Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemias, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | sapacitabine |
| Enrollment | 47 |
| Start date | Jan 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Jun 1, 2009 |
| First posted | Sep 26, 2006 |
| Last update posted | Dec 13, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: